Epithalon

Etki mekanizması

No defined receptor or molecular target protein has been described for Epithalon. No published human pharmacokinetic data exist; in particular, no systemic half-life has been measured in humans, and the “~hours” value stored in our peptide calculator is a convention, not a measurement. The most frequently cited mechanistic observation comes from a cell culture study by the originating group: in telomerase-negative human fetal fibroblasts, addition of the peptide induced expression of the catalytic telomerase subunit, measurable telomerase activity and elongation of telomeres, which the authors interpreted as reactivation of the telomerase gene (Khavinson et al., 2003). An independent group at Brunel University London reported telomere lengthening in human cell lines in 2025: in normal cells dose-dependently via hTERT and telomerase, in breast cancer cell lines via the alternative mechanism ALT (Al-Dulaimi et al., 2025). A correction published in November 2025 replaced all three primary data figures of that paper, namely telomere length, hTERT and telomerase activity, and ALT (erratum, Biogerontology 2025). Both findings come from cell culture and say nothing about systemic effects. The originating group additionally proposes a direct interaction of short peptides with DNA and a resulting modulation of gene expression; independent confirmation of this hypothesis is largely absent. Induction of telomerase is also not inherently favourable, since telomere lengthening is discussed in tumour biology as well.

Kanıt düzeyi

The reliable evidence on Epithalon is limited to cell culture and rodent studies. In a long-term study in female SHR mice, the peptide did not change mean life span but extended the life span of the last 10 percent of survivors by 13.3 percent and the maximum life span by 12.3 percent, with a 17.1 percent lower rate of chromosome aberrations; total spontaneous tumour incidence was unchanged, only leukaemia development was inhibited (6.0-fold) (Anisimov et al., 2003). In a rat study across different lighting regimes, life span was unchanged under standard illumination; maximum life span was extended under natural and under constant light, whereas the effect on tumour development appeared only under natural light, with virtually none under standard or constant illumination (Vinogradova et al., 2007). The decisive caveat is the provenance of the data: virtually all primary publications originate from the orbit of a single research group, the St. Petersburg institute and its collaborators. Independent work does exist, but is confined to cell culture and ex vivo models (Yue et al., 2022; Al-Dulaimi et al., 2025); an independent in vivo replication of the life-span findings is missing. Human data exist but support no efficacy claim for this substance: the widely cited observation in 266 elderly persons over 6 to 8 years was reported by the developing group itself and used the extract preparation Epithalamin in the pineal arm rather than the synthetic tetrapeptide AEDG (Khavinson and Morozov, 2003); MEDLINE indexes the paper as a randomized controlled trial, yet the published abstract describes neither a randomization procedure nor blinding. For the synthetic tetrapeptide itself, no controlled human trial has been published; the ClinicalTrials.gov registry lists no study for Epithalon, Epitalon, Ala-Glu-Asp-Gly or Epithalamin (query August 2026), and there is no marketing authorization as a medicine in the United States (FDA openFDA and DailyMed, query August 2026); no EU authorization is known to us either. Regulatory analytical work has, by contrast, identified Epitalon in two illegal pharmaceutical preparations (Vanhee et al., 2015). Effect sizes, safety, long-term risks and the oncological implications of telomerase induction are uncharacterized in humans; no conclusions on efficacy or safety can be drawn from this evidence base.

Araştırmayla ilgili sorular

What is Epithalon studied for in research?

Epithalon is studied predominantly in ageing research. The focus lies on cell culture work on telomerase activity and telomere length in human cells, and on rodent studies of life span, chromosome stability and spontaneous tumour development. The tetrapeptide also serves as a model substance for the hypothesis that very short peptides can regulate gene expression. All of this work is basic research and describes no human application.

Why is the evidence classed as preclinical although reports in humans exist?

Because the widely cited human report does not concern this substance: in the pineal arm of the observation in 266 elderly persons, the extract preparation Epithalamin was used rather than the synthetic tetrapeptide AEDG (Khavinson and Morozov, 2003). For AEDG itself, no controlled human trial has been published, and that is what the classification turns on. In addition, the report comes from the developing group itself: MEDLINE does index it as a randomized controlled trial, but the published abstract describes neither a randomization procedure nor blinding. Virtually all primary data also originate from a single research network, and independent in vivo replications are missing. Under our classification the substance therefore remains preclinical, regardless of how often the human observation is cited in secondary sources.

Kaynaklar

1. Khavinson et al., Bulletin of Experimental Biology and Medicine 2003DOI: 10.1023/a:1025493705728PMID: 12937682
2. Anisimov et al., Biogerontology 2003DOI: 10.1023/a:1025114230714PMID: 14501183
3. Vinogradova et al., Bulletin of Experimental Biology and Medicine 2007DOI: 10.1007/s10517-007-0441-zPMID: 18856211
4. Khavinson & Morozov, Neuro Endocrinology Letters 2003PMID: 14523363
5. Al-Dulaimi et al., Biogerontology 2025DOI: 10.1007/s10522-025-10315-xPMID: 40908429
6. Erratum zu Al-Dulaimi et al., Biogerontology 2025DOI: 10.1007/s10522-025-10326-8PMID: 41240216
7. Yue et al., Aging (Albany NY) 2022DOI: 10.18632/aging.204007PMID: 35413689
8. Vanhee et al., Drug Testing and Analysis 2015DOI: 10.1002/dta.1771PMID: 25535022